Successful treatment of granulomatosis with polyangiitis using tocilizumab combined with glucocorticoids: A case report

Tang, Peng-Fang; Xu, Long-Chuan; Hong, Wenting; Shi, Honglian

doi:10.12998/wjcc.v11.i5.1144

Cited by 2 publications

(1 citation statement)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tocilizumab, an anti-IL-6R antibody, has shown good clinical benefits in the biological treatment of patients with giant cell arteritis ( Antonio et al, 2022 ). Tang et al (2023) reported findings from a patient with refractory GPA and elevated IL-6 expression. After treatment with tocilizumab, the patient’s symptoms improved and the levels of inflammatory markers, including IL-6, normalized.…”

Section: Biologicsmentioning

confidence: 99%

Application of biological agents in the treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis

Liu,

Tian,

Chen

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) has been traditionally treated using glucocorticoids and immunosuppressants. However, these treatment modes are associated with high recurrence AAV rates and adverse reactions. Therefore, treatment strategies for AAV need to be urgently optimized. The efficacy and safety of biological agents in the treatment of vasculitis have been clinically validated. This review comprehensively summarizes the evidence-based support for the clinical use of existing biological agents in AAV. The findings reveal that multiple biological agents not only effectively reduce the adverse reactions associated with glucocorticoids and immunosuppressants but also demonstrate significant therapeutic efficacy. Notably, rituximab, an anti-CD20 antibody, has emerged as a first-line treatment option for AAV. Mepolizumab has shown promising results in relapsed and refractory eosinophilic granulomatosis with polyangiitis. Other biological agents targeting cytokines, complement, and other pathways have also demonstrated clinical benefits in recent studies. The widespread application of biological agents provides new insights into the treatment of AAV and is expected to drive further clinical research. These advancements not only improve patient outcomes but also offer more possibilities and hope in the field of AAV treatment.

show abstract

Section: Biologicsmentioning

confidence: 99%

Application of biological agents in the treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis

Liu,

Tian,

Chen

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

Critically Ill Patients with Newly Diagnosed Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: Case Series and Literature Review

Rukavina,

Zlopasa,

Vukovic Brinar

et al. 2024

JCM

View full text Add to dashboard Cite

ANCA-associated vasculitides (AAVs) are rare diseases with a prevalence of less than 200 cases per million persons and an incidence of less than 25 cases per million person-years. Their presenting features can vary from prodromal and nonspecific symptoms to dramatic organ-specific symptoms such as respiratory failure due to diffuse alveolar hemorrhage (DAH) and acute kidney injury (AKI). The latter two are hallmark features of pulmonary-renal syndrome, a potentially fatal condition that necessitates early recognition and treatment in intensive care units (ICUs) and rapid induction of immunosuppressive therapy. Background and case summaries: We described three patients with newly diagnosed AAV during the treatment of critical illness. All patients had DAH and two had AKI. The initial disease severity was extremely high in patients with myeloperoxidase (MPO)-AAV, reaching Sequential Organ Failure Assessment (SOFA) scores of 15 and 14 with predicted mortality ≥ 95.2%. Both patients needed mechanical ventilation, one additional venovenous extracorporeal membrane oxygenation (VV-ECMO), and renal replacement therapy. The patient with proteinase 3 (PR3)-AAV had a less severe disease, SOFA 3, requiring only modest oxygen supplementation and exhibiting only hematuria with normal renal function parameters. Immunosuppressive therapy was initiated during the ICU stay. The patient with the most severe clinical presentation died during the ICU stay because of sepsis, and the other two patients were discharged home. Conclusions: Patients with AAV presenting with pulmonary-renal syndrome necessitate various degrees of organ support. Nevertheless, these patients can be successfully treated in the early, critical stages of the disease and achieve remission.

show abstract

Successful treatment of granulomatosis with polyangiitis using tocilizumab combined with glucocorticoids: A case report

Cited by 2 publications

References 11 publications

Application of biological agents in the treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis

Application of biological agents in the treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis

Critically Ill Patients with Newly Diagnosed Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: Case Series and Literature Review

Contact Info

Product

Resources

About